Skip to main content

Table 2 Characteristics of breast cancer patients by propranolol and non-selective beta-blocker use in the year after diagnosis

From: Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts

  Propranolol in year after diagnosisa Non-selective beta-blocker in year after diagnosisa
Characteristic Users Non-usersb Users Non-usersc
n % n % n % n %
Country
 Belgium 984 35.7 25,021 19.2 2131 42.1 23,874 18.6
 Denmark 615 22.3 44,049 33.8 1198 23.6 43,466 33.9
 England 212 7.7 9602 7.4 299 5.9 9515 7.4
 The Netherlands 78 2.8 7252 5.6 203 4.0 7130 5.6
 Northern Ireland 70 2.5 2106 1.6 82 1.6 2094 1.6
 Republic of Ireland 142 5.2 9720 7.4 250 4.9 9612 7.5
 Scotland 400 14.5 14,740 11.3 468 9.2 14,672 11.4
 Sweden 255 9.3 18,005 13.8 436 8.6 17,824 13.9
Year of cancer diagnosis
 1995–1999 61 2.2 2495 1.9 84 1.7 2472 1.9
 2000–2004 480 17.4 27,621 21.2 832 16.4 27,269 21.3
 2005–2009 1 572 57.0 66,186 50.7 3219 63.5 64,542 50.3
 2010–2014 643 23.3 34,193 26.2 932 18.4 33,904 26.4
Age at cancer diagnosis
 <40 97 3.5 5591 4.3 110 2.2 5578 4.4
 40–49 444 16.1 19,688 15.1 540 10.7 19,592 15.3
 50–59 730 26.5 31,297 24.0 1031 20.3 30,996 24.2
 60–69 768 27.9 35,528 27.2 1419 28.0 34,877 27.2
 70–79 491 17.8 23,488 18.0 1235 24.4 22,744 17.7
 80–89 200 7.3 12,974 9.9 647 12.8 12,527 9.8
 ≥90 26 0.9 1929 1.5 82 1.6 1873 1.5
Stage
 1 965 35.0 49,458 37.9 1735 34.2 48,669 38.0
 2 927 33.6 41,797 32.0 1718 33.9 41,006 32.0
 3 284 10.3 9073 7.0 510 10.1 8847 6.9
 4 138 5.0 5086 3.9 258 5.1 4966 3.9
 Missing 442 16.0 25,081 19.2 843 16.6 24,699 19.3
Grade
 Well differentiated 365 17.2 16,827 19.7 662 17.2 16,530 19.7
 Moderately differentiated 885 41.6 34,600 40.5 1543 40.2 33,942 40.5
 Poorly differentiated 639 30.0 22,964 26.9 1109 28.9 22,494 26.8
 Missing 239 11.2 11,115 13.0 529 13.8 10,825 12.9
Cancer treatment within 6 months of cancer diagnosis      
 Surgery 2 425 88.0 114,271 87.6 4387 86.6 112,309 87.7
 Chemotherapy 1 034 37.6 46,018 35.3 1608 31.8 45,444 35.5
 Radiotherapyd 1 463 54.6 68,817 53.7 2649 53.2 67,631 53.7
Medication use in year after diagnosis
 Aromatase inhibitore 724 33.8 29,176 33.8 1459 37.7 28,441 33.6
 Tamoxifene 1 064 49.7 39,087 45.2 1765 45.6 38,386 45.3
 Statin 532 19.3 22,245 17.0 1353 26.7 21,424 16.7
 Low-dose aspirin 368 13.4 17,545 13.4 1097 21.6 16,816 13.1
  1. aRestricted to breast cancer patients living more than 1 year after diagnosis
  2. bPropranolol non-users in the year after diagnosis, but could have used other beta-blockers
  3. cNon-selective beta-blocker non-users in the year after diagnosis, but could have used other beta-blockers
  4. dRefers to radiotherapy within 6 months of breast cancer diagnosis, except in Belgium where radiotherapy was considered within 9 months
  5. eExcluding Denmark because aromatase inhibitor and tamoxifen were not recorded separately